Likorall lift warning: why a hidden safety-system fault matters beyond medical devices

What AEMPS has said

On 6 November 2026 the Spanish medicines and devices agency AEMPS warned of a risk in certain Likorall ceiling patient lifts. Its concern is a double failure. A break in the motor shaft, combined with a fault in the Single Fault Safety system, could lead to a patient fall or a sudden descent. Baxter is inspecting the affected units.

The published material does not say how many units are involved, which models or serial ranges are affected, or whether any injuries have been reported. It also gives no timeline for the inspections. Until the manufacturer's notice and the agency's full communication are checked, those points should be treated as unknown.

Why the double-failure framing matters

The warning is a useful illustration of how layered protections work. A safety system built to catch a primary failure only helps if it is itself working. If it has failed silently, the first fault is no longer contained. The harm then depends on two independent events lining up, and the second can go unnoticed for a long time.

This is a challenge for any vigilance system. A latent fault produces no adverse event on its own, so it generates no spontaneous report. It tends to surface through inspection, testing or the first serious incident. For safety teams, the lesson is that an absence of reports is weak evidence when the failure mode is hidden.

A device story on a pharmacovigilance desk

A patient lift is not a medicine, and its vigilance runs through the medical device framework, not the PV system. In the EU that means manufacturer reporting of serious incidents and field safety corrective actions, usually communicated through a field safety notice. Many QPPVs still need to follow this material. Marketing authorisation holders with drug-device combinations, hospital-facing products or in-house diagnostic support often share a safety organisation, or at least escalation routes, with device colleagues.

The same week gives a second example from the device side. A manufacturer notice published by the Dutch inspectorate IGJ describes how the Helena Laboratories V8 UltraCE analyser can place samples from two patients in one IFE block when diluent runs short. It is a different technology and a different harm, a possible sample mix-up instead of a fall. The pattern is the same: a resource or component condition under which the system behaves unsafely, communicated through a manufacturer notice.

The wider week: different levels of certainty, different actions

Set beside the other safety communications of 5-6 November, the Likorall warning shows how regulators calibrate their messages.

FDA's CBER is investigating tumour reports with Zolgensma. It cites confirmed AAV vector insertional oncogenesis involving GLI1 and says the neoplasia risk applies to both onasemnogene abeparvovec products, Zolgensma and Itvisma. The agency is assessing whether regulatory action is needed, so no outcome is known yet.

In the UK, the MHRA has issued interim advice for Duvyzat (givinostat) after international reports of deaths in patients with Duchenne muscular dystrophy. It proposes more frequent ECG and electrolyte checks. Implementation depends on an ongoing independent review, and no deaths have been reported in the UK. The advice is precautionary and the mechanism is not established in the material available.

At the routine end, the EMA published PSUSA outcomes for diethylamine-salicylate/escin and ethinylestradiol/gestodene. Both ended in maintenance of the marketing authorisations. These are a reminder that most periodic safety reviews close without new restrictions.

Each communication sits at a different point on the scale: a named failure mechanism with manufacturer action, an investigation without a decision, interim monitoring pending review, and routine maintenance. Teams should note which stage a communication has reached before deciding how to respond.

What to watch

For the Likorall case, the open questions are the scope of affected units, the corrective action Baxter will specify after its inspections, and whether other EU authorities publish parallel notices. Anyone with Likorall equipment in a facility should rely on the manufacturer's notice and the AEMPS communication, not on summaries like this one.

On the medicines side, watch for any CBER decision on the onasemnogene abeparvovec products and for the outcome of the independent review behind the MHRA's Duvyzat advice. Also note that EMA has published a Q&A for marketing authorisation holders on the CHMP nitrosamine opinion under Article 5(3), reference EMEA-H-A5(3)-1490. It is a compliance document, not a new signal, but it feeds the same quality-risk conversation. Finally, the IGJ has published an inspection report on Crinetics Pharmaceuticals Europe GmbH in Amsterdam from a January 2026 visit. The available material does not disclose findings or the type of inspection, so no conclusion can be drawn.